Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Galectin Therapeutics Q3 EPS $(0.14), Same YoY

Galectin Therapeutics Q3 EPS $(0.14), Same YoY

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.

byBenzinga Newsdesk

November 14, 2022

1 minute read

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.

Morgan Stanley Maintains Equal-Weight on Snap One Holdings, Lowers Price Target to $11

By Benzinga Newsdesk

November 10, 9:42 AM

Morgan Stanley analyst Erik Woodring maintains Snap One Holdings (NASDAQ:SNPO) with a Equal-Weight and lowers the price target from $13 to $11.

SNPO

Piper Sandler Maintains Overweight on Virtus Investment, Lowers Price Target to $268

By Benzinga Newsdesk

July 15, 6:29 AM

Piper Sandler analyst Sumeet Mody maintains Virtus Investment (NASDAQ:VRTS) with a Overweight and lowers the price target from $289 to $268.

VRTS

Earnings

Altimmune’s Earnings Outlook

By Benzinga Insights

November 6, 2:01 PM

Altimmune (NASDAQ:ALT) is set to give its latest quarterly earnings report on Tuesday, 2023-11-07. Here’s what investors need…

ALT

Beyond Air Announces Publication Of New Preclinical Data For The Treatment Of Autism Spectrum

By Benzinga Newsdesk

September 18, 4:06 PM

New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor The slow-release

XAIR

Galectin Therapeutics Q3 EPS $(0.14), Same YoY

Related Posts

Morgan Stanley Maintains Equal-Weight on Snap One Holdings, Lowers Price Target to $11

Piper Sandler Maintains Overweight on Virtus Investment, Lowers Price Target to $268

Altimmune’s Earnings Outlook

Beyond Air Announces Publication Of New Preclinical Data For The Treatment Of Autism Spectrum